Alerasool Parissa, Zhou Susu, Miller Eric, Anker Jonathan, Tsao Brandon, Kyprianou Natasha, Tsao Che-Kai
Department of Hematology-Oncology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Department of Medicine, Montefiore Medical Center Albert Einstein College of Medicine, Bronx, NY 10467, USA.
Cancers (Basel). 2025 Jan 5;17(1):147. doi: 10.3390/cancers17010147.
Oligometastatic prostate cancer (OMPC) represents an intermediate state in the progression from localized disease to widespread metastasis when the radiographically significant sites are limited in number and location. With no clear consensus on a definition, its diagnostic significance and associated optimal therapeutic approach remain controversial, posing a significant challenge for clinicians. The current standard of care for metastatic disease is to start systemic therapy; however, active surveillance and targeted radiotherapy have become attractive options to mitigate the long-term effects of androgen deprivation therapy (ADT). Furthermore, evolving biomarker methodologies may further define optimal treatment selection. In this review, we summarize the current understanding that guides the treatment of OMPC, with a focus on how host response can be an important contributing factor. Evolving scientific understanding and clinical development will continue to shape the landscape of treatment strategies for this distinct disease state.
寡转移性前列腺癌（OMPC）代表了从局限性疾病发展到广泛转移的中间状态，此时影像学上显著的转移部位在数量和位置上都有限。由于对其定义尚无明确共识，其诊断意义和相关的最佳治疗方法仍存在争议，这给临床医生带来了重大挑战。目前转移性疾病的标准治疗方法是开始全身治疗；然而，主动监测和靶向放疗已成为减轻雄激素剥夺治疗（ADT）长期影响的有吸引力的选择。此外，不断发展的生物标志物方法可能会进一步明确最佳治疗选择。在本综述中，我们总结了目前指导OMPC治疗的认识，重点关注宿主反应如何成为一个重要的促成因素。不断发展的科学认识和临床进展将继续塑造这种独特疾病状态的治疗策略格局。
